New diabetes drug tested in patients with liver issues
NCT ID NCT05427682
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial looked at how a single 50mg dose of pyroglutamate rongliflozin capsules behaves in 32 adults with mild or moderate liver damage and type 2 diabetes, compared to healthy volunteers. Researchers measured drug levels in the blood and tracked side effects to understand safety and dosing. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pyroglutamate rongliflozin capsules
What this could lead to
If successful, this study could help determine safe dosing of rongliflozin for people with liver problems and type 2 diabetes.
What could go wrong
This is a very early Phase 1 trial with only 32 participants, so results may not apply broadly. The drug's safety and effectiveness are still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China